Alkermes appoints Joshua Reed as CFO effective September 15, 2025

Alkermes plc.

Reed will report to CEO Richard Pops and join the management committee.
He brings 30+ years finance experience; most recently CFO of Omega Therapeutics and Aldeyra Therapeutics, and earlier at Bristol Myers Squibb.
Base salary $615,000, target annual cash bonus 50% of base, new-hire equity grant valued at $3.5 million.
Blair C. Jackson, EVP/COO, had been serving as interim principal financial officer; Samuel Parisi remains interim principal accounting officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.